Bausch + Lomb HomeExternal link

The STORY of Xiidra

Patients struggling with dry eye? Help break the cycle of inflammation fast and over time1*

Inflammation icon

Xiidra in action

Provides a 3-in-1 defense against dry 
eye inflammation1,2

A Vicious cycle the Xiidra difference
Symptoms relief icon

Symptom relief

Xiidra can start to deliver symptom relief in 2 weeks1*

PIVOTAL DATA DATA IN CATARACT 
PATIENTS WITH DRY EYE DATA IN SYMPTOMATIC CONTACT LENS WEARERS
Extensive coverage icon

Extensive coverage

Most patients with dry eye are covered nationwide†

access Formulary coverage PATIENT SAVINGS
Resource library icon

Resource library

Find resources to help support you, your technicians, and your patients

PEER PERSPECTIVES REQUEST SAMPLES FOR TECHNICIANS FOR PATIENT SUPPORT FAQs

The exact mechanism of action of Xiidra in dry eye disease is not known.

*Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

†Based on MMIT data from March 2025. Up to 94% of commercial and 70% of Medicare Part D patients may be covered.

Indication and important safety information

See LessSee Less

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for Xiidra.

References

  • Xiidra. Prescribing information. Bausch & Lomb Inc.
  • Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18(14):1517-1524. doi:10.1080/14656566.2017.1372748

Indication and important safety information

See MoreSee More

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.